Investigational Drug Information for BKM120
✉ Email this page to a colleague
What is the development status for investigational drug BKM120?
BKM120 is an investigational drug.
There have been 82 clinical trials for BKM120.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 7th 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Summary for BKM120
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,684 |
| WIPO Patent Applications | 1,186 |
| Japanese Patent Applications | 352 |
| Clinical Trial Progress | Phase 3 (2012-08-07) |
| Vendors | 105 |
Recent Clinical Trials for BKM120
| Title | Sponsor | Phase |
|---|---|---|
| Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | Adlai Nortye Biopharma Co., Ltd. | Phase 1 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Novartis | Phase 1 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Emory University | Phase 1 |
Clinical Trial Summary for BKM120
Top disease conditions for BKM120
Top clinical trial sponsors for BKM120
US Patents for BKM120
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
